Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Hinyokika Kiyo ; 63(7): 271-274, 2017 Jul.
Article in Japanese | MEDLINE | ID: mdl-28814707

ABSTRACT

We report three patients with frequent febrile urinary tract infections (fUTI) who underwent transurethral injection therapy with Deflux for vesicoureteral reflux (VUR). The first case was in a 52-yearold woman who was initially diagnosed with right grade II and left grade I VUR at 18 years of age. She frequently experienced fUTI due to VUR. The second case was in a 29-year-old woman. At age 23,she was diagnosed with right grade III VUR when she developed fUTI. After that,she repeatedly developed fUTI. The third case was in a 40-year-old woman who had frequently experienced fUTI since 25 years of age and had gradually become antibiotics-resistant. She was diagnosed with right grade III VUR when she was referred to our hospital. No visible reflux was confirmed by postoperative voiding cystourethrography after the patients underwent transurethral injection using Deflux. One patient developed fUTI once after surgery,but there were no perioperative complications and no recurrences. Transurethral injection using Deflux for VUR might therefore be safe and effective for treating VUR in adult female patients.


Subject(s)
Dextrans/therapeutic use , Fever/etiology , Hyaluronic Acid/therapeutic use , Urinary Tract Infections/therapy , Vesico-Ureteral Reflux/therapy , Adult , Dextrans/administration & dosage , Female , Humans , Hyaluronic Acid/administration & dosage , Injections , Middle Aged , Recurrence , Treatment Outcome , Urinary Tract Infections/complications , Vesico-Ureteral Reflux/complications
2.
Hinyokika Kiyo ; 60(9): 421-6, 2014 Sep.
Article in Japanese | MEDLINE | ID: mdl-25293794

ABSTRACT

It is very important to share patient information because home patient care involves several different specialties of care. We introduced Cybozulive ® , a cloud-based free groupware, for 14 terminal-stage patients with urological cancer to share information among doctors and co-medical staff. This system enables access to patient information regardless of time and place. Of the 14 patients (mean age 74.4 years), 11 died of cancer. The average period in which Cybozulive® was used for the patients was 210 days. The average number of entries to the electronic bulletin board in this period was 88.4. We were able to obtain more information about the patients from the website. There was no difference in the average number of times that the patient consulted the out patient clinic before and after the introduction of Cybozulive® (before 7.0 ; after 6.3). After introduction of this system, eleven patients were hospitalized in our department 21 times. Eighteen of these 21 times, since we had acquired patient information from the website beforehand, there was a quick response for management of the emergency admission. This system could be used to construct a network for home care and may be helpful for sharing patient information in homecare.


Subject(s)
Home Care Services , Terminal Care , Urologic Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Humans , Internet , Middle Aged , Patient Care Team
SELECTION OF CITATIONS
SEARCH DETAIL
...